EPISODE · Feb 11, 2026 · 9 MIN
Arecor targets phase II insuling trial for 2026 after successful 2025
from Proactive - Interviews for investors · host Proactive Investors
Arecor Therapeutics PLC's (AIM:AREC) CEO Sarah Howell talked with Proactive's Stephen Gunnion about the company’s second-half performance and its strategic priorities heading into 2026, highlighting progress across its dual focus on diabetes and oral peptide delivery. Howell explained that Arecor is a clinical-stage biopharmaceutical company focused on drug development and enhanced delivery in the cardiometabolic space. The company’s lead asset, AT278, is described as a “new unique best-in-class ultra-concentrated (500 U/mL) and ultra-rapid-acting insulin for the treatment of diabetes,” and is now progressing through a 50:50 co-development partnership with Sequel Med Tech. The collaboration is preparing for a pivotal phase two clinical study, which Arecor is targeting to begin in the second half of 2026. She noted that both teams share a vision of combining next-generation automated insulin delivery (AID) systems with next-generation insulin to improve patient outcomes and reduce disease management burden. Positive negotiations are also underway regarding a broader co-development and commercialisation partnership. On the oral GLP-1 programme, Howell highlighted the challenge of bioavailability, pointing out that Rybelsus (semaglutide), an oral GLP-1 tablet for adults with type 2 diabetes, currently achieves “less than 1% oral bioavailability.” Arecor is conducting nonclinical pharmacokinetic studies aimed at improving bioavailability, which could be highly translatable across multiple peptide therapeutics. Financially, the company reported unaudited revenues of £3.1 million for 2025 and cash of £6.1 million at year-end, extending the runway into the first half of 2027. For more insights into Arecor Therapeutics PLC’s strategy and upcoming milestones, visit Proactive’s YouTube channel, like this video, subscribe to the channel and enable notifications so you never miss future updates. #ArecorTherapeutics #SarahHowell #AT278 #DiabetesTreatment #InsulinInnovation #OralGLP1 #GLP1 #PeptideTherapeutics #BiotechNews #ClinicalTrials #Phase2Trial #MedTech #Cardiometabolic #HealthcareInnovation #ProactiveInvestors
What this episode covers
Arecor Therapeutics PLC's (AIM:AREC) CEO Sarah Howell talked with Proactive's Stephen Gunnion about the company’s second-half performance and its strategic priorities heading into 2026, highlighting progress across its dual focus on diabetes and oral peptide delivery. Howell explained that Arecor is a clinical-stage biopharmaceutical company focused on drug development and enhanced delivery in the cardiometabolic space. The company’s lead asset, AT278, is described as a “new unique best-in-class ultra-concentrated (500 U/mL) and ultra-rapid-acting insulin for the treatment of diabetes,” and is now progressing through a 50:50 co-development partnership with Sequel Med Tech. The collaboration is preparing for a pivotal phase two clinical study, which Arecor is targeting to begin in the second half of 2026. She noted that both teams share a vision of combining next-generation automated insulin delivery (AID) systems with next-generation insulin to improve patient outcomes and reduce disease management burden. Positive negotiations are also underway regarding a broader co-development and commercialisation partnership. On the oral GLP-1 programme, Howell highlighted the challenge of bioavailability, pointing out that Rybelsus (semaglutide), an oral GLP-1 tablet for adults with type 2 diabetes, currently achieves “less than 1% oral bioavailability.” Arecor is conducting nonclinical pharmacokinetic studies aimed at improving bioavailability, which could be highly translatable across multiple peptide therapeutics. Financially, the company reported unaudited revenues of £3.1 million for 2025 and cash of £6.1 million at year-end, extending the runway into the first half of 2027. For more insights into Arecor Therapeutics PLC’s strategy and upcoming milestones, visit Proactive’s YouTube channel, like this video, subscribe to the channel and enable notifications so you never miss future updates. #ArecorTherapeutics #SarahHowell #AT278 #DiabetesTreatment #InsulinInnovation #OralGLP1 #GLP1 #PeptideTherapeutics #BiotechNews #ClinicalTrials #Phase2Trial #MedTech #Cardiometabolic #HealthcareInnovation #ProactiveInvestors
NOW PLAYING
Arecor targets phase II insuling trial for 2026 after successful 2025
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.